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Abstract
This review article focuses on the risk of infections in patients with chronic obstructive pulmonary disease (COPD). Through-
out the years there have been a number of studies describing the risk of pulmonary infections in patients with COPD,
whereas only few studies have focused on the risk of infection outside the lungs.
With increasing severity of COPD the risk of respiratory tract infection also increases. The impairment of the innate immune
system is most likely responsible for both the colonization of respiratory tract with bacteria and for an increased risk of
infection with new strains of bacteria causing acute exacerbations. Also lung infections like pneumonia, lung abscess and
empyema are more often seen in patients with COPD than in healthy subjects. With regard to extrapulmonary infections, it
seems that COPD patients are not at higher risk of infection compared with subjects without COPD.
It is concluded that COPD is significantly associated with an increased risk of various respiratory tract infections, but not
with infections outside the respiratory system.
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Introduction
Chronic obstructive pulmonary disease (COPD)
is a major health problem being among the top ten
leading causes of mortality worldwide [1, 2]. In addi-
tion, in most countries COPD is related to large use of
health care resources [3]. In daily clinical practice, an
exacerbation of COPD is a very common cause for an
acute visit to the general practitioner or to an emer-
gency room and especially during the cold months of
the year also an important cause for admission to ho-
spital. In addition, it is now recognized that the fre-
quency of exacerbations plays an important role for
the perception of quality of life for the COPD patient
[4, 5]. Therefore, there has been an increased focus
on acute exacerbations in COPD, including their na-
tural history, their causes and the possibility of pre-
vention. Since respiratory tract infections are respon-
sible for more than 50% the COPD exacerbations,
a number of studies have focused on importance of in-
fection and our knowledge on this topic has expan-
ded substantially over the recent years [6].
In the last decade, there has also been a chan-
ge in the perception of COPD, which in addition
to pulmonary involvement, is now defined also to
exhibit extra-pulmonary manifestations including
a low-grade systemic inflammation [7]. Therefore,
it can be hypothesized that in addition to predi-
sposing to pulmonary infections COPD also pro-
motes extra-pulmonary infections. The topic of this
brief review is to describe the relationship betwe-
en COPD and infections, both pulmonary and
extra-pulmonary.
Epidemiological studies
The relationship between COPD and subse-
quent infection has been studied in a number of stu-
dies in the epidemiological setting. These studies
often comprise samples of the general population
including individuals with COPD. The advantage
of this approach is a large number of cases and a pos-
sibility of a comparison between participants with
and without COPD. The weakness is the fact that the
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infection, parasitic infection, pulmonary abscess/
/pyothorax, sepsis, skin infection, tuberculosis,
urinary tract infection and upper respiratory tract
infection. During the follow-up period, we obser-
ved a total of 3333 infectious disease hospitaliza-
tions. The time to first hospitalization because of
infection decreased with increasing GOLD stage
and persisted after the statistical adjustment for
background characteristics including age, gender,
smoking, alcohol consumption, comorbidity and
socioeconomic status (Figure 1). Compared with
participants without COPD as the reference group,
the Cox proportional hazards model yielded follo-
wing adjusted relative risks for infectious disease
hospitalisation: 1.06 (95% CI: 0.92–1.23) for GOLD
stage 1, 1.39 (1.24–1.56) for GOLD stage 2, and 2.21
(1.84–2.64) for GOLD stage 3 and 4, respectively,
P = 0.001). In a sub-group analysis focusing on
different types of infection, the increased risk was
associated with lower and upper respiratory tract
infections, pyothorax, and tuberculosis but not
with influenza, sepsis, skin infections, urinary tract
infections, diarrhoeal disease or other infectious
diseases (Table 1). Thus, this recent analysis con-
firmed a higher risk of pulmonary infections in
COPD, but did not show an increased risk of ho-
spitalization from extra-pulmonary infections [15].
This finding was surprising to us, as we expected
that some of the extra-pulmonary infections by
worsening the general condition of the patients
enrolled subjects are not particularly well-characte-
rized with regard to the nature of their lung disease
and that the observed infections are based on reports
from hospital records or self-reports and that micro-
biological findings are often not available.
The seminal study of Fletcher and coworkers,
who followed almost 800 men for from 1961 to
1969 in London focused on decline in lung func-
tion, respiratory symptoms, smoking and respira-
tory tract infections had a profound influence on
our understanding of natural history of COPD and
is often regarded as the prototype of such studies
[8]. Among many important findings from this stu-
dy is the fact that especially presence of chronic
mucus hypersecretion (phlegm) predisposes to re-
spiratory tract infection [8]. This finding has also
been reported in other cohorts. Already more than
30 years ago, Jedrychowski using information on
absence from work among employees of a fertili-
zer factory in Krakow, found that symptoms of
chronic bronchitis were a strong predictor of ab-
sence from work due to chest infections [9]. In The
Copenhagen City Heart Study, where we followed
a large cohort of almost 15 000 individuals selected
from the general population including patients with
COPD, we could show that mucus hypersecretion
contributed to the risk of death from COPD and that
this was mediated by respiratory infections in indi-
viduals with most severe disease [10, 11].
Using the same cohort we observed that reduc-
tion of lung function (expressed as FEV1 in percent
of the predicted value) was significantly associated
with an increased risk of hospitalization from pneu-
monia [12]. Other epidemiological studies using si-
milar methods have also reported that lung function
reduction (and presence of chronic lung disease) pre-
dicts an increased risk of pulmonary infection, in
particular community-acquired pneumonia [13, 14].
In spite of the recent focus on systemic mani-
festations of COPD, there are almost no studies
investigating the risk of extra-pulmonary infections
in patients with COPD. We recently used the Co-
penhagen City Heart Study database to study such
possible association [15]. In this study we linked
the information on the severity of COPD (according
to GOLD classification) assessed by spirometry in
1976–1978 with the number of hospital admissions
during a follow-up period of more than 25 years
in order to estimate the risk of hospital admissions
due to all infectious diseases. Based on the classi-
fication of World Health Organization Internatio-
nal Classification of Diseases we investigated fol-
lowing categories of infectious diseases: diarrho-
eal diseases, hepatitis, HIV/AIDS, influenza, lower
respiratory tract infection, meningitis, other viral
Figure 1. Time to infectious disease hospitalization in The Copen-
hagen City Heart Study Cohort according to GOLD stage. Log rank
test: P = 0.00001 (adapted from [15])
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Table 1. Incidence and risk of infectious disease hospitalization in The Copenhagen City Heart Study cohort followed for
25 years after initial diagnosis of COPD (adapted from 15)
No COPD Mild COPD Moderate COPD Severe or very Significance
N = 10190 GOLD stage 1 GOLD stage 2  severe COPD
N = 708 N = 1156 GOLD stage 3
N = 335
RR RR RR RR P value*
(95% CI) (95% CI) (95% CI) (95% CI)
Lower respiratory tract infection1, n = 1411 1.0 1.2 (1.0–1.5) 2.0 (1.7–2.3) 3.3 (2.6–4.1) < 0.0001
Upper respiratory tract infection2, n = 312 1.0 0.95 (0.54–1.67) 1.98 (1.42–2.75) 5.26 (3.55–7.78) < 0.0001
Influenza6, n = 64 1.0 0.93 (0.29–2.96) 1.27 (0.55–2.97) 1.89 (0.46–7.75) 0.78
Pulmonary abscess /pyothorax3, n = 54 1.0 0.91 (0.28–2.96) 1.32 (0.55–3.17) 6.02 (2.57–14.11) < 0.001
Tuberculosis4, n = 64 1.0 1.11 (0.39–3.11) 2.28 (1.18–4.40) 3.11 (1.19–8.15) 0.02
Urinary tract infection6, n = 714 1.0 0.96 (0.69–1.33) 0.93 (0.70–1.24) 1.16 (0.69–1.95) 0.89
Sepsis5, n = 197 1.0 1.39 (0.83–2.35) 0.92 (0.53–1.60) 1.50 (0.61–3.72) 0.48
Skin infection1, n = 401 1.0 1.01 (0.65–1.56) 1.07 (0.75–1.51) 0.67 (0.30–1.51) 0.77
Diarrhoeal disease6, n = 261 1.0 1.36 (0.83–2.23) 1.10 (0.69–1.76) 2.31 (1.14–4.69) 0.09
Other infections6, n = 844 1.0 1.01 (0.77–1.34) 1.04 (0.84–1.30) 1.08 (0.74–1.56) 0.97
N — number of participants; n — number of hospitalizations; RR — relative risk; CI — confidence interval
*P value for adjusted relative risk; 1Adjusted for sex, age, income, education, smoking, productive cough, alcohol intake and diabetes mellitus; 2Adjusted for age, income,
education, smoking, productive cough, and alcohol intake; 3Adjusted for sex, age, smoking, productive cough and diabetes mellitus; 4Adjusted for sex, age, and productive
cough; 5Adjusted for sex, age, income, alcohol intake, productive cough and diabetes mellitus; 6Unadjusted
with advanced COPD would have provoked admis-
sions to hospital as a result of a lower threshold
for admission to hospital.
Clinical studies
Contrary to epidemiological studies, the clini-
cal studies often comprise patients with well-charac-
terized COPD and include more detailed information
on the type of emerging infections. During the last
decade, particularly the East London Study of COPD
where Wedzicha and coworkers have followed a co-
hort of patients with severe COPD, and two Spanish
studies (EFRAM and DAFNE) have provided new
insight into the natural history of exacerbations in
COPD and the role of infection [16–18].
The infectious triggers of COPD exacerbations
comprise both virus and bacteria. Both types of mi-
croorganisms can trigger inflammatory reactions that
result in clinical exacerbation with dyspnea and in-
creased amount of sputum, but it seems that prono-
unced sputum purulence is a marker of bacterial in-
fection [19, 20]. Some studies report that the inciden-
ce of respiratory viral infections increases in fre-
quency almost two-fold from mild COPD to modera-
te and severe COPD [21]. The studies also suggest that
the inflammatory response to viral infection is gre-
ater in COPD, thus resulting in more prolonged cli-
nical symptoms [22]. There is evidence that viral
infection predispose to secondary bacterial infections
and that both types of microorganisms by interacting
make the exacerbations associated with presence of
both virus and bacteria more severe [23].
The airways of patients with COPD, especial-
ly severe COPD, are often colonized with bacteria.
The bacteria in question are Haemophilus influen-
zae, Streptococcus pneumoniae, Moraxella catar-
rhalis and in the most advanced disease Pseudo-
monas aeruginosa [6]. Low lung function and cur-
rent smoking are strongly associated with both high
frequency of exacerbations and with risk of colo-
nization and chronic infection [24, 25]. The per-
ception some years ago was that exacerbations
were mainly caused by an increased load of alre-
ady present bacterial strains in the airways, but
newer studies suggest that exacerbations more li-
kely are precipitated by infections with new bac-
terial strains which initiate an inflammatory re-
sponse [26].
Underlying mechanisms and consequences
of pulmonary infections in COPD
In health, a well functioning mucociliary ap-
paratus, airway and alveolar macrophages together
with secreted products comprising IgA, mucins
and antimicrobial peptides constitute an effective
defense system of the lower respiratory tract. In
COPD, several of these lines of defense are not func-
tioning optimally and this promotes bacteria to achie-
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ve a foothold in the lower airways. It seems that smo-
king itself affects host defenses negatively [25, 27].
Although one could anticipate that presence of un-
diagnosed bronchiectases would increase the exacer-
bation frequency, this was not the case in the East
London Study, although lower lobe exacerbations
were associated with more severe exacerbations and
more profound bacterial colonization [28].
The colonization or chronic infection of the
airways promotes a vicious circle impairing host
defenses and promoting further infections [6]. In
the East London Study, colonization/chronic infec-
tion was associated with frequent exacerbations and
predicted an accelerated decline of FEV1 [29].The
latter finding, although in contrast to the findings
of Fletcher et al. [8], has also been reported in a lar-
ge intervention trial, The Lung Health Study [30],
where participants with repeated exacerbations
experienced a steeper FEV1 decline than those wi-
thout exacerbations. In fact, it has been estimated
that exacerbations may account for up to 25% of the
reduction in FEV1 over time [30, 31]. Additionally,
a rapid FEV1 decline over time is associated with
more frequent episodes of lower respiratory infec-
tion [32]. Thus it seems that the vicious cycle of
infection and damage of the innate immune system
may lead to faster progression of COPD [33].
Prevention of infectious exacerbations of COPD
Because of the large influence on patients’
well-being and the course of COPD, there has been
great interest in treatments that can prevent infec-
tious exacerbations in COPD.
In this context, stopping smoking is an impor-
tant tool. In addition to having a beneficial effect
on the decline of lung function, stopping smoking
also reduces mucus hypersecretion making the air-
ways less susceptible to infections [8, 34].
Immunization against influenza can reduce the
number of exacerbations during winter months sub-
stantially and is recommended for all patients with
COPD [7, 35]. In general, the evidence for the effect
of pneumococcal vaccine for prevention of infectio-
us exacerbation in COPD is less clear than for in-
fluenza vaccination, yet also this type of immuni-
zation may be of value in COPD population [36].
Most studies of the effects of pharmacothera-
py were not particularly designed to study infec-
tious episodes in COPD, but rather to study exa-
cerbations as such. There are a number of studies
in the literature investigating possible effects of
inhaled corticosteroids, long-acting bronchodila-
tors, combination of both, mucolytics and phospo-
diesterase-4-inhibitors, with regard to prevention of
COPD exacerbations [37–42]. Although all these com-
pounds can reduce the number of exacerbations by
approximately 20–30%, the mechanism behind this
effect, although unknown, is unlikely to be a preven-
tion of infections as such, but rather an elevation of
the lung function and modification of the inflamma-
tory response to infections and other triggers of exa-
cerbations. Surprisingly, inhaled corticosteroids, al-
though reducing COPD exacerbations as such, have
been shown in both a controlled trial [38] and in
a pharmacoepidemiological study [43] to be associa-
ted with an increased risk of pneumonia.
A more direct approach with regard to preven-
tion of bacterial exacerbation is prophylactic treat-
ment with antibiotics. Although a Cochrane review
has only showed minor benefits from prophylactic
antibiotic therapy, this could be caused by the fact
that most of the studies included in this analysis
were quite old and used old-fashioned antibiotics
[44]. Macrolides have both anti-inflammatory and
antibacterial action and studies suggest that daily
treatment result in fewer and shorter exacerbations
of COPD [45, 46]. Further studies using modern
antibiotics for prophylaxis in subgroups of COPD
patients with frequent exacerbation are ongoing and
results are awaited with great interest.
In addition to above mentioned measures,
perhaps also some simple advice on daily living,
may reduce the number of chest infections. Most
importantly, since especially viruses spread by
coughing, sneezing and direct contact, it is wise
for COPD patients to minimize contacts with pe-
ople with obvious signs of airway infection (inclu-
ding taking care of their grandchildren with “snotty
noses”!). Since cold weather has been shown
to lead to bronchoconstriction and is also known
to lead to increased numbers of exacerbations
[47, 48], the patients should avoid cooling of their
bodies, by wearing appropriate cloths while being
outdoors, and even avoid going outdoors in if the
weather is particularly cold.
Conclusion
COPD is significantly associated with an incre-
ased risk of various respiratory tract infections, in
particular infectious episodes in the lower airways,
but not with infections out site the respiratory sys-
tem. These lower airway infections are responsible
for the majority of acute exacerbations of COPD and
are very likely to contribute to the faster progression
of the disease. A number of non-pharmacological and
pharmacological measures can be undertaken to re-
duce the number of infectious episodes in COPD and
to reduce the deleterious effects of these infections.
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